Models, Models, Everywhere: But Which One Should Guide Care?

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Acute myeloid leukemia (AML) treatment has evolved with targeted therapies like venetoclax.
• Accurate prognostic models are crucial for guiding treatment decisions in AML.
• Existing models may not fully capture the complexity of outcomes with novel regimens.

Purpose of the Study:

• To develop and validate a therapy-specific prognostic model for AML patients receiving venetoclax-based regimens.
• To integrate key biological features, including mutational and cytogenetic data, for improved risk stratification.
• To provide a clinically relevant framework for assessing patient survival in this evolving treatment landscape.

Main Methods:

• Retrospective analysis of patients with acute myeloid leukemia treated with venetoclax-based therapies.
• Integration of comprehensive genomic profiling (mutational analysis) and cytogenetic data.
• Development of a multivariable prognostic model to predict overall survival.

Main Results:

• The developed model effectively risk-stratified patients based on integrated mutational and cytogenetic features.
• Specific genetic markers and chromosomal abnormalities were identified as significant prognostic factors.
• The model demonstrated robust performance in predicting survival outcomes.

Conclusions:

• A novel, therapy-specific prognostic model can accurately risk-stratify AML patients on venetoclax-based regimens.
• Integrating mutational and cytogenetic data enhances prognostic accuracy.
• This framework offers a clinically valuable tool for personalized treatment strategies in AML.